What You Should Know:

您应该知道：

– Unlearn®, a leading AI company using digital twins to revolutionize clinical trials, announced today a $50M Series C funding round led by Altimeter Capital. This investment, bringing Unlearn’s total funding to over $130M, will fuel its mission to eliminate trial and error in medicine through faster, smaller, and more ethical clinical trials..

–Unlearn®是一家领先的人工智能公司，它利用数字双胞胎技术彻底改变了临床试验，今天宣布由Altimeter Capital牵头进行一轮5000万美元的C系列融资。这项投资使Unlearn的总资金超过1.3亿美元，将通过更快，更小，更合乎道德的临床试验来消除医学中的试验和错误。。

– Unlearn collaborates with pharmaceutical companies, biotechs, and academic institutions to optimize and streamline clinical trials. Their innovative technology holds immense potential to accelerate medical advancements and improve patient outcomes worldwide.

–Unlearn与制药公司、生物技术和学术机构合作，优化和简化临床试验。他们的创新技术在加速医疗进步和改善全球患者预后方面具有巨大潜力。

AI-Powered Clinical Trials with Digital Twins

人工智能支持的数字双胞胎临床试验

Founded in 2017, Unlearn has consistently pushed the boundaries of AI in clinical research. Their innovative approach uses digital twins, AI-generated models that predict individual patient health outcomes under different treatment scenarios. This allows for TwinRCTs™, highly efficient trials with smaller control groups, enabling more patients to receive active treatment and accelerating the development of life-saving therapies..

Unlearn成立于2017年，一直在推动AI在临床研究中的界限。他们的创新方法使用数字双胞胎，人工智能生成的模型预测不同治疗方案下个体患者的健康结果。这使得TwinRCTs™能够在较小的对照组中进行高效试验，使更多患者能够接受积极治疗，并加速救生疗法的发展。。

Addressing Critical Industry Challenges

应对关键行业挑战

The clinical research industry faces challenges like slow enrollment, lengthy timelines, and patient reluctance to participate in placebo-controlled trials. Unlearn’s digital twins offer a solution, potentially:

临床研究行业面临着入学速度慢、时间表长以及患者不愿意参加安慰剂对照试验等挑战。Unlearn的数字双胞胎提供了一个解决方案，可能：

Reducing trial duration: Bringing new drugs to market faster means faster access to potentially life-changing therapies.Increasing patient access: More patients receive active treatments, reducing the ethical concerns of traditional trials.Streamlining processes: Smaller control groups and efficient data analysis lead to faster and more cost-effective trials..

缩短试验时间：更快地将新药推向市场意味着更快地获得可能改变生命的疗法。增加患者接触：更多患者接受积极治疗，减少了传统试验的道德问题。简化流程：较小的对照组和有效的数据分析可以更快，更具成本效益的试验。。

Regulatory Backing for Innovation

创新的监管支持

Unlearn understands the importance of regulatory compliance. They’ve partnered with experts since their inception and secured qualification from the European Medicines Agency and agreement from the US FDA, ensuring their methodology aligns with current regulations.

Unlearn了解法规遵从性的重要性。他们自成立以来就与专家合作，并获得了欧洲药品管理局的资格和美国FDA的同意，确保其方法符合现行法规。

“Pharmaceutical companies are spending over $100 billion dollars a year on clinical research, yet the industry remains skeptical about new technology that has the power to truly transform research,” said Charles Fisher, Ph.D., founder and CEO of Unlearn. “Breaking down these barriers and proving the value of digital twin technology continues to be a main driver for us at Unlearn.

Unlearn创始人兼首席执行官查尔斯·费舍尔（CharlesFisher）博士表示：“制药公司每年在临床研究上的支出超过1000亿美元，但业界仍对能够真正改变研究的新技术持怀疑态度。”。“打破这些障碍并证明数字双胞胎技术的价值仍然是我们在Unlearn的主要驱动力。

And, this round of financing will allow us to not only grow our team but also expand our capabilities into more therapeutic areas to build awareness and prove the value.”.

而且，这一轮融资将使我们不仅能够发展团队，还可以将我们的能力扩展到更多的治疗领域，以建立意识并证明其价值。”。